The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Reijers
M H
MH
National AIDS Therapy Evaluation Centre, Department of Internal Medicine, University of Amsterdam, The Netherlands.
Weverling
G J
GJ
Jurriaans
S
S
Roos
M T
MT
Wit
F W
FW
Weigel
H M
HM
Ten Kate
R W
RW
Mulder
J W
JW
Richter
C
C
Ter Hofstede
H J
HJ
Sprenger
H
H
Hoetelmans
R M
RM
Schuitemaker
H
H
Lange
J M
JM
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir; D019258:Saquinavir